Hematology Advisor

5 days ago | hematologyadvisor.com | Jessica Nye

Ropeginterferon alfa-2b proved more effective than anagrelide in a phase 3 trial of patients with high-risk essential thrombocythemia (ET) who were resistant or intolerant to hydroxyurea. Results from this trial were presented at the EHA 2025 Congress. The trial, SURPASS-ET (NCT04285086), included 174 patients with high-risk ET who were resistant or intolerant to hydroxyurea. The patients were randomly assigned to receive either ropeginterferon alfa-2b (n=91) or anagrelide (n=83) for 52 weeks.

1 week ago | hematologyadvisor.com | Ryner Lai

Idiopathic multicentric Castleman disease (iMCD) is associated with a significant economic burden in the United States, highlighting the need for early diagnosis and the implementation of timely interventions to drive down costs, according to a poster presented at the EHA 2025 Congress. Studies indicate a clear morbidity risk associated with iMCD. Because of the diagnostic challenges associated with the disease, the true incidence and treatment burden of iMCD has been a challenge to characterize.

1 week ago | hematologyadvisor.com | Jennifer Larson

The selective exportin 1 (XPO1) inhibitor selinexor (KPT-330) showed promise in improving survival rates among pediatric patients with relapsed or refractory (R/R) leukemia in a phase 1/2 study at St. Jude Children’s Research Hospital in Memphis, Tennessee (SELHEM; NCT02212561). These findings were presented by Katelyn (Purvis) Daniels, MD, at the 2025 ASPHO Conference in Louisville, Kentucky.

1 week ago | hematologyadvisor.com | Ryner Lai

Bosutinib shows promising efficacy in the treatment of children with newly diagnosed (ND) and resistant/intolerant (R/I) Philadelphia-Chromosome positive (Ph+) chronic myeloid leukemia (CML), alongside an acceptable safety profile, according to a poster presented at the EHA 2025 Congress. Bosutinib is a second-generation tyrosine kinase inhibitor of BC::ABL1 that has received Food and Drug Administration (FDA) approval in pediatric patients of at least one year of age with ND and R/I Ph+ CML.

1 week ago | hematologyadvisor.com | John Schieszer

New treatment regimens for multiple myeloma (MM) have significantly improved over the past 2 years in a way that is leading to a meaningful positive impact for patients with MM, according to presentations at the ASCO Annual Meeting 2025. For example, an international study found that it may be possible to transition to administering immunotherapy in the convenience of a patient’s home.